Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with neoadjuvant chemotherapy + HER2-targeted therapy in high-risk HER2-positive early breast cancer
jRCT2080224179Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Atezolizumab arm with Placebo arm (2 arms). Started Dec 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224179.